Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy
AssigneeBaylor College of Medicine
InventorsXiaoliu Zhang, Fu Xinping
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.
Claims20
Use of a compound, comprising a Herpes Simplex Virus Type 2 (HSV-2) having a modified ICP10 polynucleotide therein, said modified ICP10 polynucleotide encoding an ICP10 polypeptide having ribonucleotide reductase activity and lacking protein kinase activity, in the manufacture of a medicament for selectively killing cancer cells in a host.
A method of generating an HSV-2 virus having oncolytic and fusogenic properties, comprising the steps of:
- modifying the ICP10 polynucleotide, wherein the modified ICP10 polynucleotide encodes for an ICP10 polypeptide having ribonucleotide reductase activity and lacking protein kinase activity, and
- operably linking the modified ICP10 polynucleotide with a constitutively active promoter.
A composition comprising a Herpes Simplex Virus Type 2 (HSV-2) having oncolytic and fusogenic properties wherein the HSV-2 comprises a modified ICP10 polynucleotide, said modified ICP10 polynucleotide encoding an ICP10 polypeptide having ribonucleotide reductase activity and lacking protein kinase activity, and wherein the modified ICP10 polynucleotide is operably linked to a constitutive promoter.
A composition comprising an HSV-2 viral vector comprising a modified ICP10 polynucleotide that encodes for a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity, and wherein the modified polynucleotide is operably linked to a constitutive promoter
Dependencies are inferred from the claim text.